Back to Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 4

Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control

Authors Daniel Kapitzke, Irina Vetter, Peter J Cabot

Published 15 December 2005 Volume 2005:1(4) Pages 279—297

Daniel Kapitzke1,2, Irina Vetter1,2, Peter J Cabot2

1These authors contributed equally to this work. 2School of Pharmacy, University of Queensland, 4072, Australia

Abstract: Opioid receptors are widely expressed in the central and peripheral nervous system as well as in numerous nonneuronal tissues. Both animal models and human clinical data support the involvement of peripheral opioid receptors in analgesia, particularly in inflammation where both opioid receptor expression and efficacy are increased. Immune cells have been shown to contain numerous opioid peptides such as β-endorphin (END), met-enkephalin (ENK), and dynorphin-A (DYN), although the predominant opioid peptide involved in immunecell mediated antinociception is thought to be END. These opioid-containing immune cells migrate to inflamed tissues during a complex process of recruitment by chemokines, adhesion, and extravasation. In these tissues, opioid peptide is released from the immune cells upon stimulation with corticotrophin-releasing factor (CRF), noradrenaline, and interleukin 1β (IL-1β), and the immune cells return to the local lymph node depleted of peptide. Consistent with this model, systemic immunosuppression may lead to impaired endogenous analgesia as competent immune cells are essential to achieve release of endogenous opioid peptides within inflamed tissue. A further level of complexity is added by the observation that exogenous opioids may impair immune cell function, although there is some evidence to suggest that endogenous opioid peptides do not share this immunosuppressive effect. Improving our understanding of endogenous opioid mechanisms will provide valuable insight towards the development of novel treatments for pain with improved side effect profiles.


Keywords: Opioid, analgesia, inflammation, immunosuppression, immune cell, pain

Download Article [PDF] 

Readers of this article also read:

Maraviroc: a review of its use in HIV infection and beyond

Woollard SM, Kanmogne GD

Drug Design, Development and Therapy 2015, 9:5447-5468

Published Date: 1 October 2015

Transparent, biocompatible nanostructured surfaces for cancer cell capture and culture

Cheng BR, He ZB, Zhao LB, Fang Y, Chen YY, He RX, Chen FF, Song HB, Deng YL, Zhao XZ, Xiong B

International Journal of Nanomedicine 2014, 9:2569-2580

Published Date: 22 May 2014

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities

Alawneh KM, Khassawneh BY, Ayesh MH, Smadi M

Therapeutics and Clinical Risk Management 2014, 10:363-366

Published Date: 19 May 2014

Photothermolysis mediated by gold nanorods modified with EGFR monoclonal antibody induces Hep-2 cells apoptosis in vitro and in vivo

Zhang S, Li Y, He X, Dong S, Huang Y, Li X, Li Y, Jin C, Zhang Y, Wang Y

International Journal of Nanomedicine 2014, 9:1931-1946

Published Date: 17 April 2014

Absence of the toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in Singaporean Chinese

Xiao Hui Liang, Wai Cheung, Chew Kiat Heng, De-Yun Wang

Therapeutics and Clinical Risk Management 2005, 1:243-246

Published Date: 15 October 2005

The controversy surrounding OxyContin abuse: issues and solutions

Sujata S Jayawant, Rajesh Balkrishnan

Therapeutics and Clinical Risk Management 2005, 1:77-82

Published Date: 15 July 2005